SCHEMBL1506129

SCHEMBL1506129

Cc1cc(-n2nc(Nc3cccc(Cl)c3F)cc2CC(=O)NCC2CC2)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 1/20 0.42
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ MAPK1 P28482 6/20 0.37
▸ ERBB2 P04626 5/20 0.37
▸ RIPK1 Q13546 3/20 0.37
▸ EGFR P00533 3/20 0.37
▸ GAK O14976 1/20 0.37
▸ RIPK2 O43353 1/20 0.37
▸ LYN P07948 1/20 0.37
▸ RET P07949 1/20 0.37
▸ EPHA1 P21709 1/20 0.37
▸ ERBB3 P21860 1/20 0.37
▸ EPHA2 P29317 1/20 0.37
▸ EPHB2 P29323 1/20 0.37
▸ EPHA5 P54756 1/20 0.37
▸ EPHB4 P54760 1/20 0.37
▸ EPHA4 P54764 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506045 0.92 CYP1A2 (0.40) P2RX7CYP1A2CYP2C9CNR2ERBB2
SCHEMBL10010359 0.90 P2RX7 (0.40) P2RX7IDO1MAPK1ERBB2RIPK1
SCHEMBL1506082 0.90 P2RX7 (0.45) P2RX7IDO1MAPK1ERBB2RIPK1
SCHEMBL10008796 0.88 MAPK1 (0.39) P2RX7MAPK1ERBB2RIPK1EGFR
SCHEMBL1506304 0.88 P2RX7 (0.42) P2RX7IDO1MAPK1ERBB2RIPK1
SCHEMBL1506212 0.84 RIPK1 (0.43) P2RX7IDO1MAPK1ERBB2RIPK1
SCHEMBL1506339 0.82 MAPK1 (0.41) P2RX7CNR2MAPK1TRPV1
SCHEMBL1506079 0.82 IDO1 (0.41) P2RX7IDO1MAPK1RIPK1EGFR
SCHEMBL1506117 0.82 RIPK1 (0.41) P2RX7IDO1MAPK1RIPK1HDAC3
SCHEMBL10011414 0.81 KMT2A (0.40) P2RX7ERBB2RIPK1EGFRGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791144-B2 Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines JANSSEN PHARMACEUTICA NV (BE) 2014-07-29 — — US disclosed
EP-2491024-B1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2013-11-20 — — EP disclosed
EP-2491024-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES Janssen Pharmaceutica N.V. (BE) 2012-08-29 — — EP disclosed
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines JANSSEN PHARMACEUTICA NV (BE) 2012-07-05 — — US disclosed
WO-2011033018-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines CHRM1, CHRNA1, CHRM3 P2RX7 43/4885CYP1A2 869/4885CYP2C9 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback